InvestorsHub Logo
Followers 22
Posts 1379
Boards Moderated 0
Alias Born 03/31/2017

Re: sox040713 post# 190967

Wednesday, 07/19/2017 11:34:51 AM

Wednesday, July 19, 2017 11:34:51 AM

Post# of 403325
Sox040713, another awesome post. Go Leo & IPIX!

Why you don't think B will get more than a $100M deal? Do you have similar examples to back it up? Thanks in advance for your thoughts.

Here's a recent $990M deal for a preclinical IBD drug.

Protagonist Therapeutics Enters into Worldwide Agreement with Janssen to Co-Develop and Commercialize PTG-200 for Inflammatory Bowel Disease

- Protagonist grants Janssen exclusive, worldwide rights to PTG-200, a first-in-class oral peptide IL-23 receptor antagonist currently in pre-clinical development

- Protagonist to receive a $50 million upfront payment and potentially up to an additional $940 million in development and sales milestones; double-digit tiered royalties on net sales

- Protagonist and Janssen to co-fund development through Phase 2; Protagonist retains option to co-detail U.S. prescribers

Protagonist Therapeutics and Janssen will jointly conduct the development of PTG-200 through Phase 2 clinical proof-of-concept in Crohn's disease, after which time Janssen will be responsible for development and commercialization. Per the terms of the agreement, Protagonist will have the right to co-detail PTG-200 in the United States.

www.prnewswire.com/news-releases/protagonist-therapeutics-enters-into-worldwide-agreement-with-janssen-to-co-develop-and-commercialize-ptg-200-for-inflammatory-bowel-disease-300465102.html

Quote:
I don't think B will fetch a deal more than the current market cap would value one at,

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News